Literature DB >> 28222896

Comparison of the prognostic value of Chronic Liver Failure Consortium scores and traditional models for predicting mortality in patients with cirrhosis.

Artur Gião Antunes1, Cristina Teixeira2, Ana Margarida Vaz3, Cláudio Martins2, Patrícia Queirós3, Ana Alves2, Francisco Velasco3, Bruno Peixe3, Ana Paula Oliveira2, Horácio Guerreiro3.   

Abstract

BACKGROUND AND AIM: Recently, the European Association for the Study of the Liver - Chronic Liver Failure (CLIF) Consortium defined two new prognostic scores, according to the presence or absence of acute-on-chronic liver failure (ACLF): the CLIF Consortium ACLF score (CLIF-C ACLFs) and the CLIF-C Acute Decompensation score (CLIF-C ADs). We sought to compare their accuracy in predicting 30- and 90-day mortality with some of the existing models: Child-Turcotte-Pugh (CTP), Model for End-Stage Liver Disease (MELD), MELD-Na, integrated MELD (iMELD), MELD to serum sodium ratio index (MESO), Refit MELD and Refit MELD-Na.
METHODS: Retrospective cohort study that evaluated all admissions due to decompensated cirrhosis in 2 centers between 2011 and 2014. At admission each score was assessed, and the discrimination ability was compared by measuring the area under the ROC curve (AUROC).
RESULTS: A total of 779 hospitalizations were evaluated. Two hundred and twenty-two patients met criteria for ACLF (25.9%). The 30- and 90-day mortality were respectively 17.7 and 37.3%. CLIF-C ACLFs presented an AUROC for predicting 30- and 90-day mortality of 0.684 (95% CI: 0.599-0.770) and 0.666 (95% CI: 0.588-0.744) respectively. No statistically significant differences were found when compared to traditional models. For patients without ACLF, CLIF-C ADs had an AUROC for predicting 30- and 90-day mortality of 0.689 (95% CI: 0.614-0.763) and 0.672 (95% CI: 0.624-0.720) respectively. When compared to other scores, it was only statistically superior to MELD for predicting 30-day mortality (p=0.0296).
CONCLUSIONS: The new CLIF-C scores were not statistically superior to the traditional models, with the exception of CLIF-C ADs for predicting 30-day mortality.
Copyright © 2017 Elsevier España, S.L.U., AEEH y AEG. All rights reserved.

Entities:  

Keywords:  Cirrosis hepática; Liver cirrhosis; Mortalidad; Mortality; Prognosis; Pronóstico; Sobrevida; Survival

Mesh:

Year:  2017        PMID: 28222896     DOI: 10.1016/j.gastrohep.2017.01.001

Source DB:  PubMed          Journal:  Gastroenterol Hepatol        ISSN: 0210-5705            Impact factor:   2.102


  4 in total

1.  qSOFA score not predictive of in-hospital mortality in emergency patients with decompensated liver cirrhosis.

Authors:  M Müller; J C Schefold; A B Leichtle; D Srivastava; G Lindner; A K Exadaktylos; C A Pfortmueller
Journal:  Med Klin Intensivmed Notfmed       Date:  2018-08-21       Impact factor: 0.840

2.  Screening for impaired liver function as a risk factor for drug safety at hospital admission of surgical patients.

Authors:  Dorothea Strobach; Angelika Poppele; Hanna Mannell; Monika Andraschko; Susanne Schiek; Thilo Bertsche
Journal:  Int J Clin Pharm       Date:  2019-12-05

3.  Impact of compensated cirrhosis on survival in patients with acute-on-chronic liver failure.

Authors:  Kessarin Thanapirom; Tongluk Teerasarntipan; Sombat Treeprasertsuk; Ashok Choudhury; Manoj K Sahu; Rakhi Maiwall; Viniyendra Pamecha; Richard Moreau; Mamun Al Mahtab; Yogesh Kumar Chawla; Harshad Devarbhavi; Chen Yu; Qin Ning; Deepak Amarapurkar; Chundamannil E Eapen; Saeed Sadiq Hamid; Amna Subhan Butt; Dong Joon Kim; Guan H Lee; Ajit Sood; Laurentious A Lesmana; Zaigham Abbas; Gamal Shiha; Diana A Payawal; Man-Fung Yuen; Albert Chan; George Lau; Jidong Jia; Salimur Rahman; Barjesh C Sharma; Osamu Yokosuka; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2021-11-25       Impact factor: 6.047

4.  A novel predictive model based on inflammatory markers to assess the prognosis of patients with HBV-related acute-on-chronic liver failure: a retrospective cohort study.

Authors:  Li Qiang; Jiao Qin; Changfeng Sun; Yunjian Sheng; Wen Chen; Bangdong Qiu; Xin Chen; Yuanfang Chen; Fei Liu; Gang Wu
Journal:  BMC Gastroenterol       Date:  2020-09-16       Impact factor: 3.067

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.